Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
MoonLake Immunotherapeutics (MLTX): Can Shares Reach the $30 Analyst Target?

MoonLake Immunotherapeutics (MLTX): Can Shares Reach the $30 Analyst Target?

Key Takeaways

  • The central $30 stock price target is the rounded arithmetic mean of more than a dozen current, verified analyst price targets for MoonLake Immunotherapeutics (MLTX), a clinical-stage biopharmaceutical company.
  • With shares recently trading near $12.50, reaching $30 would require a gain of roughly 140%, a very large move for a company that still generates no product revenue.
  • Individual analyst price targets are unusually wide, spanning from about $6 (a Sell rating) to $57, reflecting deep disagreement over sonelokimab's commercial potential.
  • The strongest supporting factor is positive Phase 3 data for sonelokimab in hidradenitis suppurativa and a de-risked path toward a 2026 biologics license application.
  • The biggest risks are the crowded IL-17 market, a prior Phase 3 composite miss, ongoing cash burn, and execution risk ahead of any approval or launch.
  • I also checked this using Tickeron’s AI Daily Buy/Sell Signals to monitor how market conditions are shifting for MLTX.

Analyst Price Targets and Consensus View

MoonLake Immunotherapeutics is followed by a fragmented group of sell-side analysts whose views diverge sharply. Across major aggregators, the average analyst price target clusters between roughly $28 and $31; the $30 central target used here is the rounded arithmetic mean of the most recent verified targets rather than any single firm's published "consensus." The underlying range is extraordinarily wide, from approximately $6 on the cautious end to $57 on the bullish end.

Bullish targets sit well above the stock price. Chardan Capital initiated coverage with a Buy rating and a $57 target in early November 2026, while H.C. Wainwright has reiterated a $50 target. Leerink Partners, Wedbush, BTIG, Clear Street, and Needham cluster in the $30 to $34 range. The bullish thesis rests on sonelokimab's strong Week 52 efficacy data in the Phase 3 VELA trial and a path toward regulatory filing. Cautious voices are meaningful, however: Goldman Sachs carries a Sell rating with a target around $12, and Stifel holds at $19, citing competitive and commercial concerns. This is not a tightly aligned "analyst consensus" but a genuinely divided debate.

Current Market Position and Path Toward the Target

MLTX shares have recently traded near $12.50, toward the lower end of a 52-week range of roughly $9.46 to $23.29, with a market capitalization near $1.1 billion. Reaching $30 from $12.50 would require an advance of about 140%, which must be characterized as a very large move. For context, the stock's own 52-week high is still well below the target.

The plausible path is binary and clinical-stage dependent. MoonLake does not yet report product revenue, so valuation hinges on the progress of its lead candidate, sonelokimab, a Nanobody-based therapy that inhibits IL-17A and IL-17F. Positive Week 52 data showing a 67% HiSCR75 response rate in hidradenitis suppurativa, an FDA meeting that Clear Street described as supporting a "best-in-class" label, and an expected 2026 biologics license application (BLA) provide a fundamental case for a substantially higher valuation if the program continues to deliver.

What Could Support a Move Toward the Target

  • Clinical data momentum: The VELA Phase 3 results and long-term efficacy data have strengthened confidence in sonelokimab's profile.
  • Regulatory progress: A constructive FDA meeting and a de-risked path toward a 2026 BLA submission are central to the bull case.
  • Large addressable market: TD Cowen's Phil Nadeau has cited more than $3 billion in potential peak sales for sonelokimab as it advances toward a possible 2027 launch.
  • Balance sheet runway: With roughly $537 million in cash and a net cash position, the company has funding to advance its pipeline through key milestones.
  • Favorable revisions: Several firms have raised targets or upgraded ratings through 2026, including upgrades from Wolfe Research and Rothschild & Co.

What Could Prevent the Target From Being Reached

  • Competitive IL-17 market: Sonelokimab would compete against established and emerging therapies, pressuring both market share and pricing.
  • Prior clinical setback: The VELA-2 study narrowly missed its composite analysis in September 2025, triggering sharp target cuts and lingering skepticism.
  • No current revenue: As a clinical-stage company, MoonLake is exposed to execution risk at every step toward approval and commercialization.
  • Cash burn: Negative EPS (earnings per share) and ongoing operating losses mean future dilution or financing remains a possibility.
  • Bearish analyst view: Goldman Sachs's Sell rating, near $12, underscores the genuine downside case if the commercial story falters.

Technical Levels and Market Structure

From a technical standpoint, the stock's 52-week high near $23.29 stands as a meaningful resistance level, well below the $30 target. The 200-day moving average, near $16.35, also sits overhead as a potential supply zone on any recovery. On the downside, the 52-week low near $9.46 represents the most durable support level. The stock currently trades near its 50-day moving average around $12, suggesting the shares are consolidating after a sharp de-rating from earlier highs. Rounded psychological levels of $10, $15, $20, and $25 may also influence trading behavior.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though for a clinical-stage company the path is driven more by events than by a calendar. Investors should monitor the timing and acceptance of the BLA filing, any additional efficacy or safety data for sonelokimab in hidradenitis suppurativa and psoriatic arthritis, quarterly cash burn and runway updates, competitive product launches, and analyst rating or target revisions. Regulatory decisions from the FDA will be the single most consequential catalyst for whether the stock can re-rate toward the $30 level.

Using AI Tools in My Research

I've found Tickeron's AI Daily Buy/Sell Signals helpful for tracking how market conditions and technical factors are evolving for names like MLTX. The system generates Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis, which can help identify opportunities and monitor positions more efficiently than manual review alone. In volatile clinical-stage names, these signals provide an additional layer of insight alongside fundamental developments.

Final Assessment

Can MoonLake Immunotherapeutics reach $30? The target, derived from the mean of current analyst price targets, sits roughly 140% above the recent price and would require a very large re-rating. The bull case is grounded in encouraging clinical data, a de-risked regulatory path, and substantial peak-sales potential for sonelokimab. The bear case is equally real, anchored in a crowded IL-17 market, a prior Phase 3 miss, and a Sell rating near $12 from Goldman Sachs. The outcome will likely be decided by regulatory and clinical events rather than valuation alone, and neither the $30 level nor any other figure should be treated as a guarantee. Investors should focus on the BLA timeline, competitive developments, and the company's cash runway as the key variables between here and the target.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MLTX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


MLTX in upward trend: 10-day moving average crossed above 50-day moving average on November 11, 2026

The 10-day moving average for MLTX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Indicator exited the oversold zone, 10 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MLTX as a result. In 81 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.

MLTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 162 of 181 cases where MLTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

MLTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.498). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
Dorfstrasse 29
Phone
+41 415108022
Employees
130
Web
https://www.moonlaketx.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.